Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2020

View Archived Issues

Preclinical pilot study data presented for NX-P004 programme in IPF

Bristol-Myers Squibb identifies MGAT2 inhibitors for metabolic disorders

Tyrosine kinase controls AD tau aggregation in vivo

A novel thermally stable mRNA vaccine candidate protects mice against SARS-CoV-2 challenge

Islet organoids can evade immune attack

NSC-801845, a novel cytidine analogue with excellent activity in number of tumor models

First-in-human data presented for the live-attenuated RSV vaccine, RSVdeltaG

Janssen presents new anti-influenza nucleosides

New CDK2/cyclin E inhibitors discovered at Pfizer

Velexbru granted supplemental approval in Japan

Femtogenix discloses G-A crosslinking cytotoxic agents

New KDM1A inhibitors synthesized at Hanmi Science

Jiangsu Chia Tai Tianqing Pharmaceutical, Medshine Discovery patent PARP-1 inhibitors

FDA approves Xeomin for its first pediatric indication

Mechanisms of retinopathy come into focus

Targeting SARS-CoV-2 papain-like protease suppresses viral infection and promotes antiviral immunity

Opthea completes meeting with FDA and EMA for phase III clinical program of OPT-302 in wet AMD

First-in-class anticancer therapy ErSO targets estrogen receptor alpha-positive breast cancer

Roche begins phase II study of GDC-9545 for postmenopausal women with untreated early breast cancer

European Commission approves Kaftrio with ivacaftor for cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...